Generation of strip-format fibrin-based engineered heart tissue (EHT)

Methods in Molecular Biology

Volumn 1181, Issue , 2014, Pages 121-129

  Schaaf, Sebastian ^a   Eder, Alexandra ^b   Vollert, Ingra ^a   Stöhr, Andrea ^a   Hansen, Arne ^a   Eschenhagen, Thomas ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

Author keywords

Cardiomyocytes; Engineered heart tissue; Fibrin; Neonatal rat heart cells; Tissue engineering

Indexed keywords

FIBRIN; FIBRINOGEN; SILICONE; THROMBIN; SEPHAROSE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL CULTURE; CELL ISOLATION; CLINICAL PROTOCOL; CULTURE MEDIUM; ENGINEERED HEART TISSUE; HEART; HEART MUSCLE CELL; NONHUMAN; PRIORITY JOURNAL; RAT; TISSUE ENGINEERING; ANIMAL; CHEMISTRY; CYTOLOGY; DRUG EFFECTS; PROCEDURES; TISSUE SCAFFOLD;

ANIMALS; FIBRIN; MYOCYTES, CARDIAC; RATS; SEPHAROSE; TISSUE ENGINEERING; TISSUE SCAFFOLDS;

EID: 84925884115     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4939-1047-2_11     Document Type: Article

References (9)

1. Zimmermann W-H, Schneiderbanger K, Schubert P, Didié M, Münzel F, Heubach JF, Kostin S, Neuhuber WL, Eschenhagen T (2002) Tissue engineering of a differentiated cardiac muscle construct. Circ Res 90(2):223-30
2. Eschenhagen T, Fink C, Remmers U, Scholz H, Wattchow J, Weil J, Zimmermann W-H, Dohmen HH, Schäfer H, Bishopric N, Wakatsuki T, Elson EL (1997) Three- dimensional reconstitution of embryonic cardiomyocytes in a collagen matrix: a new heart muscle model system. FASEB J 11(8):683-94
3. Eschenhagen T, Eder A, Vollert I, Hansen A (2012) Physiological aspects of cardiac tissue engineering. Am J Physiol 303(2):H133-43
4. Tiburcy M, Didié M, Boy O, Christalla P, Döker S, Naito H, Karikkineth BC, El-Armouche A, Grimm M, Nose M, Eschenhagen T, Zieseniss A, Katschinksi DM, Hamdani N, Linke WA, Yin X, Mayr M, Zimmermann W-H (2011) Terminal differentiation, advanced organotypic maturation, and modeling of hypertrophic growth in engineered heart tissue. Circ Res 109(10):1105-14
5. Zimmermann W-H, Melnychenko I, Wasmeier G, Didié M, Naito H, Nixdorff U, Hess A, Budinsky L, Brune K, Michaelis B, Dhein S, Schwoerer A, Ehmke H, Eschenhagen T (2006) Engineered heart tissue grafts improve systolic and diastolic function in infarcted rat hearts. Nat Med 12(4):452-8
6. Hansen A, Eder A, Bönstrup M, Flato M, Mewe M, Schaaf S, Aksehirlioglu B, Schwoerer AP, Schwörer A, Uebeler J, Eschenhagen T (2010) Development of a drug screening platform based on engineered heart tissue. Circ Res 107(1):35-44
7. Hirt MN, Sörensen NA, Bartholdt LM, Boeddinghaus J, Schaaf S, Eder A, Vollert I, Stöhr A, Schulze T, Witten A, Stoll M, Hansen A, Eschenhagen T (2012) Increased afterload induces pathological cardiac hypertrophy: a new in vitro model. Basic Res Cardiol 107(6):307
8. Schaaf S, Shibamiya A, Mewe M, Eder A, Stöhr A, Hirt MN, Rau T, Zimmermann W-H, Conradi L, Eschenhagen T, Hansen A (2011) Human engineered heart tissue as a versatile tool in basic research and preclinical toxicology. PloS One 6(10):e26397
9. Stöhr A, Friedrich F, Flenner F, Geertz B, Eder A, Schaaf S, Hirt MN, Uebeler J, Schlossarek S, Carrier L, Hansen A, Eschenhagen T (2013) Contractile abnormalities and altered drug response in engineered heart tissue from/ Mybpc3/-targeted knock-in mice. J Mol Cell Cardiol 63:189-98